Allarity Therapeutics, Inc. (ALLR)

In November 2025, Allarity Therapeutics reported its Third Quarter financial results, with an EPS of -$0.19, beating estimates. In September 2025, the company presented Phase 2 clinical data for stenoparib/2X-121, showing a median overall survival exceeding 25 months in advanced ovarian cancer patients. In August 2025, the company's shares surged after its ovarian cancer therapy received FDA Fast Track Designation and provided a Second Quarter update, highlighting clinical progress, IP expansion, and new partnerships. In July 2025, Allarity announced a new licensing and laboratory services agreement with an EU-based biotechnology company. In March 2025, Allarity announced a new Phase 2 trial evaluating stenoparib in combination with temozolomide for recurrent small cell lung cancer (SCLC), authorized a share repurchase program, settled with the SEC, and had a securities class action lawsuit dismissed, and reported its Full Year 2024 financial results, outlining a strategic realignment to focus solely on stenoparib. In February 2025, Allarity announced it would begin enrollment for a new Phase 2 protocol to advance stenoparib toward FDA approval in advanced ovarian cancer patients and expanded its Phase 2 clinical trial for stenoparib in advanced ovarian cancer. In April 2024, the company implemented a 1-for-20 reverse stock split to regain Nasdaq bid price compliance.

Allarity Therapeutics, Inc. does not exhibit traditional demand seasonality. The demand for cancer therapeutics and companion diagnostics is driven by ongoing medical needs, disease prevalence, clinical trial progress, and regulatory approvals, rather than seasonal fluctuations.

Allarity Therapeutics, Inc. is a clinical-stage precision medicine biopharmaceutical company focused on developing personalized cancer treatments using its proprietary Drug Response Predictor (DRP®) technology. Their lead drug candidate is stenoparib, being evaluated in a Phase 2 clinical trial for advanced ovarian cancer, along with its companion diagnostic stenoparib-DRP. In 2024, the company narrowed its focus to stenoparib.

Allarity Therapeutics, Inc. operates in Denmark and the United States. The company's headquarters are located in Boston, Massachusetts, U.S., and it maintains an R&D facility in Hoersholm, Denmark.

Allarity Therapeutics' brand reputation has been influenced by positive clinical advancements and resolutions of past compliance and legal issues. Receiving FDA Fast Track Designation for stenoparib and positive Phase 2 clinical data boosted investor confidence and scientific credibility. Expansion of intellectual property and initiation of a new Phase 2 SCLC trial showcased innovation and external validation. The company addressed challenges related to Nasdaq listing compliance and finalized a settlement with the SEC, positively impacting its reputation by removing uncertainties.

Allarity Therapeutics, Inc. is owned by a mix of institutional shareholders (6.53%), insiders (11.05%), and retail investors (82.41%). Major institutional owners include Private Advisor Group, LLC, Vanguard Group Inc, and Geode Capital Management, Llc. Leon Sass is the largest individual shareholder, owning 1.09 million shares, representing 6.87% of the company. Thomas Jensen is another insider owner.